Monopar Therapeutics (MNPR) Net Cash Flow (2017 - 2025)

Monopar Therapeutics has disclosed Net Cash Flow across 9 years of filings, most recently posting -$65.9 million for Q4 2025.

• Net Cash Flow for Q4 2025 came in at -$65.9 million, down 265.69% year-over-year; the trailing twelve-month figure through Dec 2025 was $15.9 million (down 58.7% YoY), and the FY2025 annual result was $15.9 million, down 58.7% from the prior year.
• Net Cash Flow came in at -$65.9 million for Q4 2025 at Monopar Therapeutics, down from $88.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $88.2 million in Q3 2025 to a low of -$65.9 million in Q4 2025.
• The 5-year median for Net Cash Flow is -$1.6 million (2021), against an average of $2.3 million.
• Across the five-year window, Net Cash Flow tumbled 2814.45% in 2021 and soared 84636.59% in 2025, its largest moves.
• Monopar Therapeutics' Net Cash Flow stood at -$2.0 million in 2021, then tumbled by 198.16% to -$6.1 million in 2022, then surged by 128.92% to $1.8 million in 2023, then jumped by 2162.54% to $39.8 million in 2024, then sank by 265.69% to -$65.9 million in 2025.
• The last three Net Cash Flow figures came in at -$65.9 million (Q4 2025), $88.2 million (Q3 2025), and -$206922.0 (Q2 2025), per Business Quant data.